gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027 - PubMed (original) (raw)

gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027

Denise Drudy et al. Emerg Infect Dis. 2007 Mar.

No abstract available

PubMed Disclaimer

Similar articles

• Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
  Walkty A, Boyd DA, Gravel D, Hutchinson J, McGeer A, Moore D, Simor A, Suh K, Taylor G, Miller M, Mulvey MR; Canadian Nosocomial Infection Surveillance Program. Walkty A, et al. Diagn Microbiol Infect Dis. 2010 Apr;66(4):419-24. doi: 10.1016/j.diagmicrobio.2009.12.002. Diagn Microbiol Infect Dis. 2010. PMID: 20226332
• High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
  Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, Fanning S. Drudy D, et al. J Antimicrob Chemother. 2006 Dec;58(6):1264-7. doi: 10.1093/jac/dkl398. Epub 2006 Oct 3. J Antimicrob Chemother. 2006. PMID: 17018563
• Clostridium difficile-associated diarrhoea.
  Elliott B, Chang BJ, Golledge CL, Riley TV. Elliott B, et al. Intern Med J. 2007 Aug;37(8):561-8. doi: 10.1111/j.1445-5994.2007.01403.x. Intern Med J. 2007. PMID: 17640189 Review.
• Clostridium innocuum: Microbiological and clinical characteristics of a potential emerging pathogen.
  Cherny KE, Muscat EB, Reyna ME, Kociolek LK. Cherny KE, et al. Anaerobe. 2021 Oct;71:102418. doi: 10.1016/j.anaerobe.2021.102418. Epub 2021 Jul 28. Anaerobe. 2021. PMID: 34332070 Free PMC article. Review.

Cited by

• Antibiotic Resistances of Clostridioides difficile.
  Spigaglia P, Mastrantonio P, Barbanti F. Spigaglia P, et al. Adv Exp Med Biol. 2024;1435:169-198. doi: 10.1007/978-3-031-42108-2_9. Adv Exp Med Biol. 2024. PMID: 38175476
• Phylogenomic analysis of Clostridioides difficile ribotype 106 strains reveals novel genetic islands and emergent phenotypes.
  Roxas BAP, Roxas JL, Claus-Walker R, Harishankar A, Mansoor A, Anwar F, Jillella S, Williams A, Lindsey J, Elliott SP, Shehab KW, Viswanathan VK, Vedantam G. Roxas BAP, et al. Sci Rep. 2020 Dec 17;10(1):22135. doi: 10.1038/s41598-020-79123-2. Sci Rep. 2020. PMID: 33335199 Free PMC article.
• How Oxygen Availability Affects the Antimicrobial Efficacy of Host Defense Peptides: Lessons Learned from Studying the Copper-Binding Peptides Piscidins 1 and 3.
  Oludiran A, Courson DS, Stuart MD, Radwan AR, Poutsma JC, Cotten ML, Purcell EB. Oludiran A, et al. Int J Mol Sci. 2019 Oct 24;20(21):5289. doi: 10.3390/ijms20215289. Int J Mol Sci. 2019. PMID: 31653020 Free PMC article.
• Proteotyping of Clostridioides difficile as Alternate Typing Method to Ribotyping Is Able to Distinguish the Ribotypes RT027 and RT176 From Other Ribotypes.
  Emele MF, Joppe FM, Riedel T, Overmann J, Rupnik M, Cooper P, Kusumawati RL, Berger FK, Laukien F, Zimmermann O, Bohne W, Groß U, Bader O, Zautner AE. Emele MF, et al. Front Microbiol. 2019 Sep 10;10:2087. doi: 10.3389/fmicb.2019.02087. eCollection 2019. Front Microbiol. 2019. PMID: 31552001 Free PMC article.
• Whole genome analysis reveals new insights into the molecular characteristics of Clostridioides difficile NAP1/BI/027/ST1 clinical isolates in the People's Republic of China.
  Lv T, Chen Y, Guo L, Xu Q, Gu S, Shen P, Quan J, Fang Y, Chen L, Gui Q, Ye G, Li L. Lv T, et al. Infect Drug Resist. 2019 Jul 1;12:1783-1794. doi: 10.2147/IDR.S203238. eCollection 2019. Infect Drug Resist. 2019. PMID: 31308704 Free PMC article.

References

1. 1. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am. 2001;30:753–77. 10.1016/S0889-8553(05)70209-0 - DOI - PubMed
2. 1. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile–associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis. 2004;38:646–8. 10.1086/382084 - DOI - PubMed
3. 1. Johnson S, Samore MH, Farrow KA, Killgore GE, Tenover FC, Lyras D, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med. 1999;341:1645–51. 10.1056/NEJM199911253412203 - DOI - PubMed
4. 1. Kuijper EJ, Coignard B, Tull P. the ESCMID Study Group for Clostridium difficile (ESGCD), EU Member States and the European Centre for Disease Prevention and Control (ECDC). Emergence of Clostridium difficile–associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2–18. 10.1111/j.1469-0691.2006.01580.x - DOI - PubMed
5. 1. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–84. 10.1016/S0140-6736(05)67420-X - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information